Boston Scientific shares fall 5% on cybersecurity incident and product recall

Josh Kohn-Lindquist, The Motley Fool Wed, August 26, 2026 at 2:31 PM PDT | 3 min read

• BSX
• ABT
• MDT
• ^IXIC

Boston Scientific (NYSE: BSX), a global medical device maker, closed at $48.17, down 3.38%. Premarket reports indicated that a cybersecurity incident disrupted global operations and shipping. The company also announced a product recall for certain types of its percutaneous catheters, further weighing on the stock. Investors are watching how quickly the company restores its systems and whether the recall exacerbates the interruption. Trading volume reached 31.8 million shares, approximately 48% above its three-month average of 21.4 million shares.

How the Markets Moved Today

• S&P 500 (SNPINDEX: ^GSPC) fell 0.04% to 7,675.
• Nasdaq Composite (NASDAQINDEX: ^IXIC) slipped 0.08% to 26,130.
• Abbott Laboratories (NYSE: ABT) closed at $114.10, down 1.75%.
• Medtronic (NYSE: MDT) finished at $92.01, up 0.95%.

Boston Scientific's cybersecurity disruption stood out among its medical device and interventional medtech peers.

What This Means for Investors

Boston Scientific's stock has dropped 55% over the last year, and today's double dose of bad news did not help. The product recall is tied to the company's ENROUTE Transcarotid Neuroprotection System (NPS), following FDA concerns about the potential separation of the product's arterial sheath tip.

Compounding the issue, the company disclosed a cybersecurity incident that disrupted its global operations, potentially affecting the processing and shipping of customer orders. Management stated it was working to restore lost functions but could not yet determine whether the event would have a material impact on BSX shares.

Following several quarters of weaker-than-expected earnings, disappointing Watchman sales, slashed guidance, and a major acquisition now weighing on Boston Scientific's balance sheet, the stock has shifted from a steady compounder to more of a turnaround or value type of stock — especially after today's news. While BSX stock remains on my watch list, I would need to see positive developments before considering a purchase.

Should You Buy Stock in Boston Scientific Right Now?

Before you buy stock in Boston Scientific, consider this:

The Motley Fool Stock Advisor analyst team has identified what they believe are the 10 best stocks for investors to buy now — and Boston Scientific was not among them. The 10 stocks that made the cut could produce significant returns in the coming years.

Consider when Netflix made this list on December 17, 2004: if you invested $1,000 at the time of the recommendation, you would have $443,461. Or when Nvidia made this list on April 15, 2005: if you invested $1,000 at the time of the recommendation, you would have $1,307,633.

Stock Advisor's total average return is 973% — outperforming the S&P 500's 213%. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »